ARTICLE | Clinical News
BDM-E: Completed Phase I/II enrollment
May 7, 2007 7:00 AM UTC
BDM completed enrollment of 192 patients in a double-blind, Russian Phase I/II trial. Patients will receive daily 10 µg doses of subcutaneous BDM-E or placebo for 10 days. ...